The above results suggest that the Vpr peptide treatment may induce the exposure of CRT and enhance the pro-phagocytic signal, leading to the upregulation of the phagocytosis-inhibitory molecule CD47 in the tumor. The gene discussed is CD47; the disease is neoplasm.